This inventor holds 1 USPTO granted patent. Top assignee: Hitachi Chemical Company, Ltd.. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: Hirotomo Kato: Innovator in Equine Interleukin Research
Introduction
Hirotomo Kato is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the study of equine interleukin-1. His work has implications for veterinary medicine and immunology.
Latest Patents
Hirotomo Kato holds a patent for "DNA encoding equine interleukin-1." This patent discloses an equine interleukin-1 peptide that comprises a sequence of at least five continuous amino acids, represented by SEQ ID NO: 1 or NO: 2 in the sequence listing. The patent also includes DNA coding for the equine interleukin-1 peptide, a recombinant vector containing the DNA, a transformant with the recombinant vector, and a process for preparing an anti-equine interleukin-1 antibody using the equine interleukin-1 peptide as an antigen. He has 1 patent to his name.
Career Highlights
Hirotomo Kato is associated with Hitachi Chemical Company, Ltd., where he applies his expertise in biotechnology. His work at the company has allowed him to explore innovative solutions in the field of equine health.
Collaborations
Hirotomo has collaborated with notable colleagues such as Shigeyoshi Takagi and Noriko Nakamura. Their combined efforts have contributed to advancements in their respective research areas.
Conclusion
Hirotomo Kato's contributions to the field of biotechnology, particularly through his patent on equine interleukin-1, highlight his role as an innovator in veterinary medicine. His work continues to influence the development of treatments for equine health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile